Fundz

Veinway Closes Oversubscribed Safe Round And Begins Series A Round

PRIVATESep 07, 2023

Round Type

Series A

Or YehudaBiotechnologyHealth CareMedical

Description

VeinWay has closed an oversubscribed SAFE round of investment and has opened a series A round.

Who else raised in Medical and Biotechnology around the same time

Companies in the same sectors as VeinWay that raised within 45 days of this round, from Fundz verified event records.

  • VitaTek raised an undisclosed amount (Series A) on October 22, 2023.
  • Actym Therapeutics raised $60M (Series A) on October 18, 2023.
  • Homed-IQ raised $1.1M (Seed) on October 17, 2023.
  • Purple Biotech raised $5.4M on October 17, 2023.
  • Greenbrook TMS raised $1.5M (Seed) on October 13, 2023.
  • Streamex Corp. raised $861K (Seed) on October 12, 2023.

Who to call at VeinWay, and when

A new round usually means VeinWay is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day VeinWay raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at VeinWay, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at VeinWay. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

VeinWay

Location

Or Yehuda, Tel Aviv District, Israel

About

VeinWay Ltd is a medical device company founded in 2020 by Jordan Pollack within the MEDX Xelerator incubator as a response to the clinical unmet need focused on Chronic Venous Occlusions (CVOs). Discussions conducted between 2021-2022 with established physicians from Europe, Israel and the US revealed that crossing CVOs is one of the largest unmet needs in interventional radiology today, with failure rates estimated between 10%-17%. Because of how cumbersome it is to recanalize chronically occluded veins, few physicians perform the procedure and thus, only around 10-13% of patients who need a venous stent actually receive one. VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment VeinWay raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for VeinWay's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

VeinWay raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.